Montano, Ryan <br/><br/>
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.  [electronic resource] 

 -  Molecular cancer therapeutics  Feb 2012 
 - 427-38 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-11-0406  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antimetabolites--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Blotting, Western<br/>Camptothecin--analogs & derivatives<br/>Cell Cycle Checkpoints--drug effects<br/>Cell Line<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Checkpoint Kinase 1<br/>Cytarabine--pharmacology<br/>DNA Breaks, Double-Stranded--drug effects<br/>DNA Damage<br/>Deoxycytidine--analogs & derivatives<br/>Dose-Response Relationship, Drug<br/>Drug Screening Assays, Antitumor<br/>Drug Synergism<br/>Flow Cytometry<br/>Humans<br/>Hydroxyurea--pharmacology<br/>Irinotecan<br/>Molecular Structure<br/>Phosphorylation--drug effects<br/>Protein Kinase Inhibitors--chemistry<br/>Protein Kinases--metabolism<br/>Pyrazoles--chemistry<br/>Pyrimidines--chemistry<br/>Staurosporine--analogs & derivatives<br/>Gemcitabine